

Research update Biosergen: First patient treated in phase Ib study a success

Carlsquare Equity Research has updated its view on Biosergen following the progress made in India and the report for the second quarter.

[Read the full update here.](#)

About Carlsquare

Carlsquare is a global research firm and financial advisor, focusing on M&A, Equity Research and Growth Equity. Carlsquare has 150 employees with deep sector knowledge in all 11 GICS sectors. The senior equity research team has extensive experience about the stock environment and several business sectors. The team produces company research reports, independent valuations and trading notes. The group have offices in Canada, Denmark, France, Germany, Poland, Sweden, United Kingdom and United States. [Read more](#)

Contacts

MARKUS AUGUSTSSON

Head of Equity Research

markus.augustsson@carlsquare.com

+46 (0)76 235 03 20

NIKLAS ELMHAMMER

Senior Equity Analyst

niklas.elmhammer@carlsquare.com

+46 (0)70 898 39 59

Attachments

[Research update Biosergen: First patient treated in phase Ib study a success](#)